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Abstract
Background: HIV-1-infected and immune competent brain mononuclear phagocytes (MP; macrophages and microglia)
secrete cellular and viral toxins that affect neuronal damage during advanced disease. In contrast, astrocytes can affect
disease by modulating the nervous system’s microenvironment. Interestingly, little is known how astrocytes communicate
with MP to influence disease.
Methods and Findings: MP-astrocyte crosstalk was investigated by a proteomic platform analysis using vesicular stomatitis
virus pseudotyped HIV infected murine microglia. The microglial-astrocyte dialogue was significant and affected microglial
cytoskeleton by modulation of cell death and migratory pathways. These were mediated, in part, through F-actin
polymerization and filament formation. Astrocyte secretions attenuated HIV-1 infected microglia neurotoxicity and viral
growth linked to the regulation of reactive oxygen species.
Conclusions: These observations provide unique insights into glial crosstalk during disease by supporting astrocyte-
mediated regulation of microglial function and its influence on the onset and progression of neuroAIDS. The results open
new insights into previously undisclosed pathogenic mechanisms and open the potential for biomarker discovery and
therapeutics that may influence the course of HIV-1-mediated neurodegeneration.
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Introduction
Astrocytes comprise more than 50% of total cells in brain and
serve pivotal homeostatic and regulatory functions for maintaining
blood-brain barrier and neuron integrity [1,2]. This is made
possible by their functional roles in regulating extracellular
glutamate, supporting a glial-neuronal network, controlling
neuronal physiologic activities, promoting neurogenesis and
secretion of neurotrophins [3–5]. Growing evidence suggests that
human immunodeficiency virus type one (HIV-1) infection of the
central nervous system (CNS) may affect some of these functions
and contribute to neuropathogenesis in distinct pathways (re-
viewed in [6–8]).
Astrocytes serve as natural host cells for HIV-1 particularly in
advanced brain disease [9–13]. Moreover, HIV and gp120 bind
efficiently to astrocytes [14–18], but during both in vitro and in
vivo HIV infection only in a small proportion of infected astrocytes
can be detected [11,13,14,16,19]; a restriction that has recently
been attributed to absence of CD4 on astrocytes and limited virus
entry [20–22]. Productive infection of human astrocytes with
HIV-1 has significant effects on cell physiology in vitro [23,24] and
is associated with measurable neuropathology in a mouse model
[25]. Thus infected astrocytes, although infrequent, can have
localized pathogenic effects. At another level, as part of brain
parenchyma, astrocytes are likely exposed continuously to HIV-1
particles, viral gp120, Tat proteins, cytokines, and other
substances secreted by HIV-1-infected macrophages and microg-
lia. Studies in vitro indicate that many of these products
significantly modulate astrocyte physiology, which in turn can
alter essential interactions of astrocytes with other cells in the
brain, particularly neurons. For example, exposure of cultured
astrocytes to HIV and gp120 induces extensive changes in cellular
gene expression [8,26–28] and impairs transport of extracellular
glutamate by astrocytes [29,30]; a defect which may lead to
neuronal death by glutamate excitotoxicity [31]. HIV-1, recom-
binant gp120, and viral transactivator Tat activate astrocytes to
secrete the pro-inflammatory cytokines TNF-a, IL-6, and IL-1b;
the pro-inflammatory chemokines MCP-1 and IP-10; and
neurotoxic nitric oxide (NO) [11,30–38], all of which could
contribute to the overall inflammatory environment in the brain.
Glutamate uptake can also be impaired by intracellular expression
of recombinant Tat or exposure of astrocytes to TNF-a [32,33].
PLoS ONE | www.plosone.org 1 June 2008 | Volume 3 | Issue 6 | e2507Additional insight into physiological effects of Tat on astrocytes
was obtained in recent studies using proteomics, which revealed
decreased synthesis of products such as phosphatase 2A inhibitor,
the mitochondrial enzyme isocitrate dehydrogenase, and a-
tubulin/vimentin with concomitantly increased levels of heme
oxygenase 1, heat shock protein 70, and iNOS [34,35]. Overall,
these findings suggest that astrocytes rendered dysregulated by
exposure to HIV-1 in the brain have the capacity to injure or
impair neurons. Because both HIV-1 binding and native infection
can affect astrocyte function in vitro and in vivo [24,25,30],
astrocytes possess a pathogenic potential that exceeds their
susceptibility to HIV-1 infection.
In contrast to the large body of work on astrocyte-neuronal
interactions, there is surprisingly little information on the
potential cross-talk between astrocytes and macrophages/microg-
lia in the context of HIV infection. Yet until recently, HIV
mediated neuropathogenesis was considered to revolve solely
around metabolic processes induced by viral infection and
activated mononuclear phagocytes (MP: perivascular macrophag-
es and microglia) [36–38]. The role of brain MP in the
pathobiology of neuroAIDS rests as a cell source for pro-
inflammatory neurotoxic products and as a continuous reservoir
for productive viral replication [39–41]. Activated astrocytes can
exert both protective and detrimental effects on neurons [42,43].
Astrocytes have been shown to accelerate neurotoxic brain MP
activities and regulate such responses [19,25,44,45], but how and
under what conditions this occurs and the intercellular effects
remain unknown. Although it is well known that HIV-1
replication and innate immune responses in the brain are limited
in the early stages of viral infection [40,41,46], the relative
contributions of cytotoxic T lymphocytes or glial cells to this
process are unclear.
The present study posits that astrocyte–microglial crosstalk
contributes to control of HIV mediated neuropathogenesis.
Previous research performed in our laboratories demonstrated
that macrophage neurotoxicity was affected in the setting of HIV-
1 infection and astrocyte co-cultivation [47]. Astrocytes may exert
regulatory roles in disease depending on the MP activation state
[42,43]. These studies focused on the cellular control mechanisms
that influence cognitive and motor dysfunctions in HIV-1-infected
individuals, but left unresolved a wide range of questions that
could only now be addressed through the advent of proteomics,
live cell confocal microscopy, and new murine model systems for
study of HIV infection. For the first time, we were able to conduct
our experiments with HIV-infected isogeneic primary mouse
macrophages and astrocytes, thus minimizing the heterogeneity of
cellular responses observed when using human cells from multiple
donors. This approach build on recent findings demonstrating that
primary mouse cells including macrophages, lymphocytes, and
astrocytes can support efficient HIV replication when infected
with HIV carrying envelope proteins that recognize mouse cell
receptors, such as HIV pseudotyped with vesicular stomatitis virus
(VSV)-G protein [48,49] or recombinant HIV expressing MuLV
gp80 envelope, EcoHIV [50–52]. Using VSV/HIV for infection
of mouse cells and proteomic approaches to investigate the effects
of astrocytes on HIV-1-infected microglia, we show herein that
microglial F-actin polymerization, filament formation, and cell
migration are altered by astrocyte secretions. Astrocytes modulate
microglial activation by regulating reactive oxygen species and cell
death pathways that regulate viral growth. Such astrocyte-
microglial crosstalk profoundly affects microglial structural and
secretory functions that in turn affect the pathobiology of disease
leading to disease onset and neuroAIDS progression in an infected
human host.
Results
Neurotoxic activities of HIV-1/VSV pseudotype infected
microglial
To preclude inter-strain variation, microglia and astrocytes
were obtained from identical inbred mouse strains. HIV-1
infection was facilitated in murine cells by circumventing necessary
HIV-1 co-receptors by using a HIV-1/VSV pseudotyped virus.
This model provided productive infection of microglia and
microglia-astrocyte cross-talk responses in the absence of genetic
mismatches. To substantiate the capacities of microglial and
astrocyte secretory responses to affect neuronal toxicity, we
measured neuronal cell death in primary neuron cultures after
24 hour exposure to conditioned media (CM) from cultures of
infected microglia alone, astrocytes alone, or infected microglia co-
cultured with astrocytes at a ratio of 1:2 in transwell systems
(Fig. 1). Expression of microtubule associate protein-2 (MAP-2,
green) and the neuronal nuclei-specific protein, neuron-specific
nuclear protein (NeuN, red) demonstrated that .98% of the cells
were indeed neurons. After culture in the presence of CM from
uninfected microglia and/or astroctyes, the levels of apoptotic
neurons were relatively low (2.8%–4.3%) as determined by the
percentage of neurons stained by terminal uridine deoxynucleo-
tidyl transferase dUTP nick end labeling (TUNEL, green) and the
total number of neuronal nuclei stained with DAPI. In contrast,
CM from infected microglia increased neurotoxicity as shown by
the 10-fold increase (22.9%) compared to CM from uninfected
microglia. However, this neurotoxic response was attenuated with
CM from infected microglia co-cultured with astrocytes as
demonstrated by a significant diminution (.2 fold, 10.1%) of
apoptotic neurons (n=5, p,0.01).
HIV-1/VSV infected microglial proteome
We next evaluated the proteome of the virus-infected microglia
to determine the protein compositions associated with the
observed neurotoxic responses. We reasoned that the microglial
proteome was affected by HIV-1 infection and that regulation of
specific proteins was linked to microglial neurotoxic activities and
HIV-1 induced neurodegeneration. To test this idea, we employed
a 2D difference gel electrophoresis (DIGE) proteomics platform to
assess changes of the microglial proteome and its affects by
astrocyte co-cultivation (Fig. 2). Following cultivation of uninfected
or virus-infected microglia in the presence or absence of astrocytes,
lysates from uninfected and infected microglia were labeled with
the N-hydroxy-succinimidyl ester of carboxycyanine (Cy3) and 1-
(5-carboxypentyl)-1-methylindodi-carbocyanine halide (Cy5), re-
spectively, and a mixture of lysates from both groups were labeled
by 1-(5-caboxypentyl)-1-propylindocarbocyanine halide (Cy2).
From virus-infected microglial lysates cultured in the absence of
astrocytes, 2116 spots were digitally detected, of which 77 spots
were differentially expressed as determined by either a 50%
increase or decrease in protein spot volume compared with those
from uninfected microglia. Those spots were robotically selected
and excised, digested with trypsin, and subjected to analysis by
liquid chromatography-tandem mass spectrometry (LC/MS/MS)
(Fig. 2). From these spots, 39 and 24 proteins were confirmed to be
up- or down-regulated, respectively, in infected microglia, of
which 14 were identified. These proteins were grouped into
functional classes as structural, regulatory, or enzyme according to
the description provided by the ExPASy Proteomics Server
Classification (http://ca.expasy.org/) (Table 1). Proteins, includ-
ing cofilin and MARCKS, proliferation marker PCNA, and the
energy ‘‘linked’’ protein, pyruvate kinase, were down-regulated
after viral infection, whereas calmodulin was up-regulated.
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PLoS ONE | www.plosone.org 2 June 2008 | Volume 3 | Issue 6 | e2507Figure 1. Neurotoxic activities of culture fluids from HIV-1/VSV infected microglia attenuated by microglia-astrocyte co-cultivation.
Mouse neurons were cultured for 10 d and exposed to the 20% conditioned media (CM) from uninfected or HIV-1/VSV infected microglia and/or
astrocytes for 24 h. MAP-2 (green) and NeuN (red) expression by neurons was visualized by immunohistochemical staining. Characteristic
neurotoxicity, including released nuclear materials and broken neurites, were observed in neurons treated with CM from HIV-1/VSV infected microglia
alone. Percentages of apoptotic neurons were evaluated by the ratio of TUNEL
+ (green) neurons to DAPI
+ (blue) cells. The results are depicted as a
mean percentage of apoptotic cells6SEM of three experiments. Significant reduction of percentage of apoptotic cells were observed in HIV-1/VSV
infected co-cultures and astrocyte groups, compared with those of neurons cultured in microglial CM alone (n=3 determines/group, p,0.01,
determined by one-way ANOVA analysis and Tukey’s multiple comparison post-hoc tests). Bars for MAP-2/NeuN, 20 mm; bars for DAPI and TUNEL,
50 mm.
doi:10.1371/journal.pone.0002507.g001
Microglia-Astrocyte Crosstalk
PLoS ONE | www.plosone.org 3 June 2008 | Volume 3 | Issue 6 | e2507In contrast, lysates from infected microglia co-cultured with
astrocyte showed 149 and 360 spots that were up- or down-
regulated proteins, respectively from a total of 2043 proteins
(Fig. 2). Three hundred and seventy-six spots were picked, digested
and analyzed by LC/MS/MS; from which 68 proteins were
identified and similarly classified (Table 2). After infection, serine/
threonine phosphatase 2A (PP2A) and biliverdin reductase were
up-regulated; whereas tubulin-a, enolase-a and ferritin were
down-regulated (Fig 2). Expression levels of 7 proteins identified
by mass spectrometry were validated by Western blot assays in 3
independent experiments, each with triplicate determinations.
Interestingly, cross comparison of the two different cell culture
models revealed PP2A levels in microglia co-cultured with
astrocytes were reduced compared to those in single cell type
cultures (n=3, p,0.01) (Fig 2).
Microglial networks
We next examined the biological networks of microglial proteins
affected by astrocytes and viral infection via dynamic pathway
modeling (Ingenuity Pathway Analysis (IPA), IngenuityH Systems,
Figure 2. Proteome of HIV-1/VSV infected microglia (MCG) and MCG co-cultured with astrocytes (AST). DiGE analyses of lysates of
uninfected and HIV-1/VSV infected microglia cultured alone (MCG, upper gel) or in the presence of astrocytes (MCG+AST, lower gel) Proteins from
uninfected microglia lysates are labeled with Cy3 (green), whereas those from HIV-1/VSV infected microglia are labeled with Cy5 (red). After merging,
proteins exhibiting no changes appear yellow in the DiGE image, down-regulated proteins in green, and up-regulated proteins in red. Three-
dimensional DeCyder interpretation for seven representative proteins identified by mass spectrometry and corresponding Western blot analysis are
shown around the DiGE images. Each pair of protein spots (Cy3-and Cy5-labeled) are 3D views of their relative peak volumes. The peak area
comprising the entire volume represents the distribution of the protein spot in the gel, whereas the volume correlates to the protein concentration.
The consecutive numbers of spots located in the respective DiGE images correspond to the protein volumes shown.
doi:10.1371/journal.pone.0002507.g002
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(Table 2) from the microglia-astrocyte co-culture group were
searched with the corresponding Swissprot access numbers for
their exact gene counterparts in IPA. The gene counterparts and
their respective levels of changes were uploaded to the IPA
module. IPA generated 2 high-scoring networks for pathways
associated with cell assembly and organization, scoring 51 and
involving 26 proteins (Fig. 3A) and cell death, scoring 34 and
involving 17 proteins (Fig. 3B).
Interestingly, for regulated proteins associated with cell
assembly and origination, 2 nodes of interest involving actins
and NFkB were uncovered (Fig. 3A). Cell locomotion involves a
cyclical process that requires cell protrusions at its leading edge
and retractions at its trailing edge. Actin plays crucial roles in both
processes. Microglial actins in astrocyte-co-cultures were down-
regulated after HIV-1/VSV infection and the proteins related to
actin binding, polymerization and stability, including MARCKS,
moesin, Wiskott-Aldrich syndrome protein (WAS) and gelsolin,
were all up-regulated. The down-regulation of these proteins
suggests a less migratory phenotype after infection (Fig. 3A).
Additionally, activation of NFkB is essential for microglia
activation, however, direct agonists, glia maturation factor beta
(GMFB) and phospholipase C beta 4, were down-regulated also
suggesting a down-regulated phenotype associated with HIV-1/
VSV infection.
IPA indicated that 8 of the microglial protein changes in
infected microglia were related to increased cell death in
eukaryotic cells (Fig 3B). Those down-regulated proteins included
annexin A1, adenomatous polyposis coli protein, sarcoplasmic
reticulum 2+-Ca-ATPase, enolase-a, GMFB and galectin-3; while
up-regulated proteins included programmed cell death 6-interact-
ing protein and PP2A. Interestingly, 6 of the protein changes
associated with attenuation of cell death were down-regulated
including galectin-3 and peroxiredoxin-1, whereas gelsolin,
moesin, cytovillin and programmed cell death 6-interacting
protein were up-regulated.
Cytoskeletal transformation
We next performed morphological and immunochemical
quantification to validate findings indicated by our pathway
modeling of infected microglia-astrocyte (MCG-AST) interactions.
Immunohistochemistry for expression of tubulin-a was used to
assess microglial migratory morphologies that included protrusion
formation and tailing structure, while assessment of F-actin
expression was utilized to observe polarization; all essential
features necessary for cell locomotion [53]. In addition, expression
of vimentin and ionized calcium binding adaptor molecule 1 (Iba-
1) was assessed to determine cell activation and purity. TNF-a was
used as positive control for inducing activation and locomotion of
microglia.
Tubulin-a expression by microglia demonstrated 2 distinct
morphologies; a resting cell morphology which was characterized
by ramified, elongated, and rounded cells, and a migratory cell
morphology consisting of polarized and tailing structures [54]
(Fig. 4A). Migratory morphologies in virus-infected, single cell-type
cultured microglia (MCG) predominated; however, elongated cells
were substantially increased in microglia co-cultured with
astrocytes (MCG-AST) without significant changes in tubulin-a
expression among the treatment groups as determined by mean
fluorescence intensity (Fig. 4B). Infection of microglia with HIV-1/
VSV resulted in increased levels of F-actin polarized cells
compared to uninfected microglia (Fig. 4A and C). Co-culture of
infected microglia with astrocytes diminished levels of F-actin
polarized microglia compared with infected microglia cultured in
the absence of astrocytes (p,0.01). Iba-1 staining showed .98%
of the identified cells were microglia (Fig. 4A). As demonstrated by
increased mean fluorescence intensities, HIV-1/VSV infection of
Table 1. Changes in the proteome of HIV-1/VSV infected microglia.
Regulation and
Protein Class Protein Name
Swissprot
Access No. Fold Change
a M.W. Da pI
b Peptides
c
Up-regulated
Structural LOC683313 protein Q4FZU2 1.5 59249 8.03 3
Myotrophin P62774 1.5 12861 5.28 2
Regulatory Tyki protein Q3U5Q7 1.9 46835 6.09 6
Proteasome activator complex subunit 1 P97371 1.6 28673 5.83 4
Calmodulin P62204 1.7 16838 4.09 7
Enzymes Adenine phosphoribosyltransferase P08030 1.5 19736 6.31 2
Down-regulated
Structural 40S ribosomal protein SA P14206 1.7 32838 4.74 2
Cofilin-1 P18760 1.6 18560 8.22 3
Beta-actin FE-3 Q99NC5 1.6 14983 5.65 2
Proliferating cell nuclear antigen P17918 1.7 28785 4.66 2
Regulatory Gelsolin P13020 1.6 85942 5.83 5
MARCKS (myristylated alanine-rich protein kinase C
substrate)
P26645 1.5 29661 4.34 7
Heterogeneous nuclear ribonucleoprotein K Q5FWJ5 1.5 51028 5.19 3
Enzymes Pyruvate kinase isozyme M2 P52480 1.6 57845 7.42 2
aCompared with uninfected microglia.
bTheoretical isoelectric point calculated by Swissprot database at http://ca.expasy.org/sprot/.
cNumber of peptides detected by mass spectrometry for each identified protein.
doi:10.1371/journal.pone.0002507.t001
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Regulation and
Protein Class Protein Name
Swissprot
Access No. Fold Change
a M.W. Da pI
b Peptides
c
Up-regulated
Structural Dynein O88487 1.6 68393 5.16 9
Moesin P26041 1.7 67738 6.00 7
Lamin A Q3U733 2.2 72427 6.54 5
Lamin B2 P21619 1.6 67029 4.25 6
Cytovillin P26040 1.7 69434 6.00 4
Microtubule plus end-directed kinesin motor 3A P28741 1.9 80168 6.16 3
L-plastin Q61233 1.8 70149 5.20 3
Radixin P26043 1.5 68525 5.85 8
GPI-anchored protein p137 Q60865 1.8 73547 5.24 4
Regulatory HSP70 protein, mitochondrial P38647 1.9 68525 5.91 9
Heterogeneous nuclear ribonucleoprotein M Q9D0E1 1.5 77648 9.01 3
Coronin-7 Q9D2V7 1.6 100812 5.13 5
Vacuolar ATP synthase catalytic subunit A P50516 1.6 68267 5.13 14
Sorting nexin-1 Q9WV80 1.7 58951 4.25 13
MARCKS (myristylated alanine-rich protein kinase C substrate) P26645 1.7 29644 4.34 6
Protein kinase C and casein kinase substrate in neurons
protein 2
Q9UNF0 1.8 55738 5.08 2
Major vault protein Q9EQK5 1.9 95951 5.43 9
Programmed cell death 6-interacting protein Q9WU78 2.1 96009 6.15 4
DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 Q922B8 1.5 82499 6.94 4
Wiskott-Aldrich syndrome protein family member 2 Q8BH43 1.6 54073 5.38 4
Rap2-interacting protein x Q9D394 1.7 53006 5.36 3
Gelsolin P13020 1.7 85900 5.83 10
Rho GTPase-activating protein 25 Q8BYW1 1.7 73382 6.03 7
Enzymes Methylenetetrahydrofolate dehydrogenase Q922D8 1.7 10099 6.68 9
Ubiquitin carboxyl-terminal hydrolase 5 Q3U4W8 2.6 93354 4.94 10
Transitional endoplasmic reticulum ATPase Q01853 1.8 89307 5.14 7
Serine/threonine-protein phosphatase 2A 65 kDa regulatory
subunit A alpha isoform (PP2A)
Q76MZ3 1.8 65150 5.00 4
Aconitase P28271 3.0 82652 6.64 11
Thimet oligopeptidase 1 Q8K2D4 1.7 78026 5.67 3
Vacuolar ATP synthase catalytic subunit A P50516 1.6 68267 5.13 14
NADH dehydrogenase (ubiquinone) Fe-S protein 1 Q5SUH2 1.6 79748 5.51 5
Biliverdin reductase A Q9CY64 1.6 33524 6.53 6
Down-regulated
Structural Annexin A2 P07356 3.3 38676 7.55 3
Annexin A1 P10107 3.0 38734 6.97 6
Annexin A3 O35639 2.5 36370 5.33 3
Alpha-tubulin 6 P68373 2.3 49909 4.96 7
Tropomyosin-3 P21107 1.6 32862 4.68 5
40S ribosomal protein S14 P62264 2.5 16272 10.10 2
Beta-actin P60710 2.9 41737 5.29 2
Regulatory Coactosin-like protein Q9CQI6 1.8 15944 5.28 3
Glia maturation factor beta Q9CQI3 1.9 16736 5.07 6
Rho, GDP dissociation inhibitor (GDI) beta Q5M860 1.9 22850 4.98 3
Galectin-3 P16110 2.5 27366 8.47
14-3-3 zeta P63101 3.0 27771 4.73 5
Kinesin light chain 4 Q9DBS5 1.7 68612 5.76 2
Regulating synaptic membrane exocytosis protein 2 [Fragment] Q9JIS1 1.8 175803 9.45 9
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ed microglia (n=3, p,0.05) (Fig 4A and D). These levels were
comparable to levels attained by activation of uninfected microglia
with TNF-a. However co-culture of infected microglia with
astrocytes diminished vimentin expression (n=3, p,0.01, com-
pared to infected microglia cultured alone) to levels attained by co-
culture with uninfected microglia (n=3, p.0.05).
Astrocytes modulate microglial cell death
We next sought to validate microglial cell death pathways,
which were implicated by IPA network analysis, and used caspases
as a protein marker for cell death induction. Multiple intracellular
caspases were labeled with fluorescent-labeled inhibitor of caspases
(FLICA) and mean fluorescence intensity (MFI) was quantified by
confocal microscopy of uninfected or infected microglia cultured
in the presence or absence of astroctyes. Microglia cultured with
TNF-a was used as positive control for activated microglia.
Minimal caspase expression was observed in uninfected microglia
as determined by the low fluorescence signal, however treatment
with TNF-a induced over a 3-fold increase in caspase levels
(P,0.01) (Fig 5A and B). HIV-1/VSV infection of microglia and/
or co-culture with astrocytes up-regulated caspase expression
compared to uninfected microglia (n=5, p,0.01). Notably,
microglia in all astrocyte co-cultures showed higher caspase levels
than the uninfected without cell-cell cultivation (Fig. 5A), however
no significant differences in caspase expression as determined by
FLICA stain and MFI could be discerned (Fig. 5B). On the other
hand, caspase-3 expression as determined by Western blot was
consistent with immunochemical assays showing increased levels
of p 31 and p 17 in microglia after culture in the presence of HIV-
1 and/or astrocytes and HIV-1 (Fig. 5C). Most importantly, co-
culture with astrocytes significantly reduced levels of HIV-1 p24
expression by infected microglia compared to those cultured in the
absence of astrocytes (n=3, p,0.01) (Fig. 5D), suggesting that
astrocytes suppress viral replication within infected microglia.
Together, these results demonstrate the ability of astrocyte co-
culture to activate cell death pathways in infected microglia, thus
diminishing the capacity for productive viral replication.
Astrocytes influence macrophage migratory responses
Based on the capacity of HIV-1 infection to mobilize
monocyte/macrophage migration to sites of neuroinflammation,
we evaluated the capacity of microglia-astrocyte interactions to
govern locomotion of bone marrow-derived macrophages (BMM).
To assess the extent of migration by laser confocal microscopy live
imaging, we monitored the mobility of 5-chloromethylfluorescein
diacetate (CMFDA)-labeled BMM cultured in chemotaxis cham-
bers with media alone or CM obtained from infected microglia in
the presence or absence of astrocytes. Increased trafficking of
BMM cultured in the presence of microglia-astrocyte CM was
prevalent by 60 minutes after initiation of culture and migration
speed peaked by 180 minutes post-initiation compared to medium
Regulation and
Protein Class Protein Name
Swissprot
Access No. Fold Change
a M.W. Da pI
b Peptides
c
Ferritin light chain 1 P29391 2.4 20802 5.66 6
5-hydroxytryptamine 2B receptor Q02152 1.9 56508 9.05 7
GRP1 binding protein [Fragment] Q920B1 4.1 119873 8.82
Microtubule-associated protein RP/EB family member 1 Q61166 2.4 30015 5.12 2
Adenomatous polyposis coli protein [Fragment] Q61315 2.0 310898 7.44 5
Alcohol dehydrogenase [NADP+] Q9JII6 3.7 36432 6.90 7
Fatty acid binding protein 4, adipocyte P04117 1.9 14650 8.53 2
Enzymes Nicotinamide nucleotide transhydrogenase Q61941 2.4 113838 7.53 5
Sarcoplasmic reticulum 2+-Ca-ATPase P11507 3.1 114768 5.23 4
Phenylalanyl-tRNA synthetase, mitochondrial Q99M01 1.6 52303 6.68 5
Triosephosphate isomerase P48500 4.3 26848 6.89 10
Calpain-12 Q9ER56 2.1 80588 5.91 9
Glutathione S-transferase Mu 1 P10649 1.8 25822 8.33 3
Fructose-bisphosphate aldolase A P05064 3.3 39200 8.30 4
Peroxiredoxin-1 P35700 3.0 22176 8.26 7
Alpha-enolase P17182 2.0 47140 6.37 6
Cathepsin A P16675 2.0 53843 5.56 2
Lysozyme P08905 1.6 16689 9.11 2
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, beta
A2A5N2 2.1 28086 4.77 12
Heat-responsive protein 12 P52760 3.1 14255 8.73 2
Phospholipase C, beta 4 Q6P8L2 2.0 53261 5.47 5
Proteasome (prosome, macropain) subunit, alpha type 3 Q58EV4 3.0 28405 5.29 2
aCompared with uninfected microglia.
bTheoretical isoelectric point calculated by Swissprot database at http://ca.expasy.org/sprot/.
cNumber of peptides detected by mass spectrometry for each identified protein.
doi:10.1371/journal.pone.0002507.t002
Table 2. Cont.
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PLoS ONE | www.plosone.org 7 June 2008 | Volume 3 | Issue 6 | e2507Figure 3. Ingenuity Pathway Analysis. Dynamic pathway/network modeling of the microglial proteome was afforded by integration of protein/
gene data to the Ingenuity Pathway Analysis software of IngenuityH Systems. Generated pathways show significant correlations with cellular
assembly and organization (A) and cell death (B) networks. Interactions between proteins are shown by lines, whereas the lines with arrows represent
direct interactions and no-arrow lines indicate binding only. Solid lines show the direct interaction, while the broken lines show indirect interaction.
Nodes are represented by shapes and colors. Functions are indicated by shapes: diamonds for enzymes, squares for cytokines, rectangles for ligand
dependant nuclear factors, triangles for kinases, ovals for transcription regulators, trapezoids for transporters, and circles indicate other interactions.
Red color nodes represent the microglial proteins which are up-regulated upon HIV-1/VSV infection, while the green color nodes represent down-
regulated proteins. Nodes without color represent proteins not input by user, but interpreted by the database as highly probable interactions within
the network. The abbreviation used are: ACO1, aconitase; ACTB, beta-actin; ANXA1, annexin A1; ANXA2, annexin A2; APC, adenomatous polyposis coli
protein; ATP2A2, sarcoplasmic reticulum 2+-Ca-ATPase; ATP6V1A, vacuolar ATP synthase catalytic subunit A; BLVRA, biliverdin reductase A; CAPRIN1,
GPI-anchored protein p 137; COTL1, coactosin-like protein; DDX1, dead (Asp-Glu-Ala-Asp) box polypeptide 1; FABP4, fatty acid binding protein 4;
FRMD4B, GRP1 binding protein; FTL1, ferritin light chain 1; GMFB, glia maturation factor beta; GSN, gelsolin; HSPA9, heat shock protein 70; LGALS3,
galectin-3; LYZ, lysozyme; LMNA, lamin A; LMNB2, lamin B2; MARCKS (includes EG:4082), myristylated alanine-rich protein kinase C substrate; MAPRE1,
microtubule-associated protein; MSN, moesin; PDCD6IP, programmed cell death 6-interacting protein; MVP, major vault protein; NDUFS1, NADH
dehydrogenase (ubiquinone) Fe-S protein 1; NNT, nicotinamide nucleotide transhydrogenase; PACSIN2, protein kinase C and casein kinase substrate
in neurons protein 2; PLCB4, phospholipase C beta 4; PRDX1, peroxiredoxin-1; RDX, radixin; RPS14, 40S ribosomal protein S14; TPI1, triosephosphate
isomerase; TPM3, tropomyosin-3; TUBA1C, alpha-tubulin 6; USP5, ubiquitin carboxyl-terminal hydrolase 5; VCP, transitional endoplasmic reticulum
ATPase; VIL2, cytovillin; WASF2, Wiskott-Aldrich syndrome protein family member 2; YWHAZ, tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein beta.
doi:10.1371/journal.pone.0002507.g003
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media or microglial CM; however astrocyte and microglia-
astrocyte CM induced robust levels of BMM migration (Fig. 6B).
This level of BMM migration was attenuated by wiskostatin
(WISK), a specific inhibitor of neural Wiskott-Aldrich syndrome
protein (N-WASP)-mediated actin polymerization and by latrun-
culin A (LatA), an F-actin inhibitor. These results were consistent
with the mean migration speed. BMM migrated at
59.7612.1 nm/min (mean6SEM) in fresh media and
88.8621.2 nm/min in microglial CM (Fig 6C). CM from
astrocytes increased BMM migration speed to 204.4634.0 nm/
min and microglia-astrocyte CM increased migration to
245.3652.4 nm/min (p,0.01 compared to speed with media or
microglial CM). Treatment with WISK or LatA diminished the
speed of microglia-astrocyte CM-induced BMM migration to
37.965.3 nm/min and 27.464.6 nm/min, respectively (p,0.01).
Figure 4. Immunohistochemical validation of proteomic profiling. Uninfected or HIV-1/VSV infected microglia were cultured for 24 h in the
absence (MCG) or presence of astrocytes (MCG+AST). This arbitrary time point was chosen as it reflected dynamic changes in cell-cell interactions.
Uninfected microglia cultured in the presence of 20 mg/ml TNF-a for 6 hours served as an activated microglia control. (A) Microglia were stained for
the expression of the cytoskeletal proteins tubulin-a (green) and F-actin (red); the specific microglial marker ionized calcium binding adaptor
molecule 1 (Iba-1) (red); and the activation indicator, vimentin (green). DAPI staining of nuclei shows total number of microglia. Arrowheads point to
migratory morphologies. Scale bar, 20 mm; original magnification, 663. Quantification of (A) tubulin-a, (B) F-actin, and (C) vimentin expression was
performed via laser confocal microscopy and the ratio of overall fluorescence to cell numbers was calculated by digital image analysis using Image-
Pro Plus version 5.1 software (Media Cybernetics, Inc.). Significant differences in mean fluorescence6SEM for n=5 determinations/group was
performed by one-way ANOVA and Tukey’s post-hoc multiple comparisons where p,0.05 was considered significant.
doi:10.1371/journal.pone.0002507.g004
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PLoS ONE | www.plosone.org 9 June 2008 | Volume 3 | Issue 6 | e2507Figure 5. Caspase in HIV-1/VSV microglial infections. Uninfected or HIV-1/VSV infected microglia were cultured for 24 h in the absence (MCG)
or presence of astrocytes (MCG+AST), Uninfected microglia cultured in the presence of 20 mg/ml TNF-a for 6 hours served as an activated microglia
control. (A) Microglia were treated with a fluorescent-labeled inhibitor of caspases (FLICA; Immunochemistry Technologies, Bloomington, MN) to
detect poly-caspases. Scale bar, 20 mm; original magnification, 663. (B) Quantification of poly-caspase expression as detected with FLICA was
achieved by fluorescence microscopy and digital image analyses using Image-Pro Plus version 5.1 software (Media Cybernetics, Inc.) to calculate the
ratio of overall fluorescence due to FLICA staining to that obtained by DAPI stained nuclei. Differences in mean poly-caspase fluorescence6SEM for
n=5 determinations/group was assessed by one-way ANOVA and Tukey’s post-hoc tests for multiple comparisons. *p,0.05, significant compared
with uninfected single cultured microglia.
#p,0.05, significant compared with other 4 groups. (C) Western blot analysis of caspase-3 p 31 and p 17
levels showed trends consistent with FLICA analysis. Densitometric analysis of p 31 and p 17 levels were normalized to GAPDH levels and mean6SEM
were determined for n=5 determinations. Differences between means were determined by one way ANOVA and Tukey’s post-hoc test for multiple
comparisons where *p,0.05. (D) Western blot analysis showing HIV-1 p24 expression in cultures of infected microglia alone (MCG) or co-cultures
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phage chemotactic protein-1 (MCP-1), which showed distinct
affects on macrophage mobility (our unpublished observations).
Discussion
In the present study, we demonstrate that secreted products
from astrocytes have a profound affect on the phenotype of HIV-1
infected microglia. This occurs, in measure, by the ability of
astrocytes to modulate networks of MP death and cell migration.
Specifically, astrocyte-microglial crosstalk leads to increases in
microglial proteins affecting the assembly and projection of
filaments and projections. Changes in severing and capping
proteins lead to morphological changes in microglia consistent
with an elongated resting phenotype. Coincident with these
activities, astrocytes affect microglial metabolic activities and
stimulate cell death pathways. Reduced HIV-1 p24 expression is
coincident with a lowering of neurotoxic responses of infected
microglia. Such complex cell-cell communication processes are
likely linked to disease tempo and significance. These observations
lead to the question as to how astrocytes control viral replication in
brain MP and how astrocytes regulate ongoing neurotoxicity. To
answer these questions, we used primary mouse cells as targets for
HIV infection and a proteomic approach to explore astrocyte
cross-talk with HIV infected microglia. Our results provide new
insights into molecular mechanisms of astrocytes regulating HIV-
infected microglia.
Proteomics is a powerful, high-throughput approach for study of
cellular responses to biological stimuli at the protein level, but the
utility of the method depends on the uniformity and reproduc-
ibility of the cellular systems under investigation. Although the
present studies should ideally be conducted with human cells,
primary astrocytes and microglia can only be obtained from
abortive human fetal tissues and multiple tissue acquisitions from
multiple donors are required. To ensure homogeneity of cellular
targets in the present study, we elected to conduct this work with
primary astrocytes and microglial cells obtained from a single
inbred mouse strain. Rodent cells have been widely used in studies
on the role of HIV Tat, gp120, and other viral proteins in
neuroAIDS [55–59]. Since mouse or rat CD4 is not recognized as
receptors for cellular entry by HIV, it has been generally assumed
that mouse cells are resistant to HIV infection. Nonetheless,
engagement of yet known viral receptors on rodent cells by HIV or
soluble gp120 can affect cell signaling pathways and often cell
death in neural cells [29,60]. Recent studies indicate however that
this restriction is operational primarily at the virus entry level.
Primary mouse cells can be infected after circumventing the block
to viral entry by using either HIV pseudotyped with the VSV-G
protein [48,49] or recombinant HIV expressing the MuLV gp80
envelope, EcoHIV [50]. EcoHIV was also shown to be infectious
and neuropathogenic in normal immunocompetent mice [50–52],
thus creating a model for studies of HIV pathogenesis in small
animals. Cells from transgenic rats expressing human CD4 and
CCR5 receptors, as well as the transgenic animals, can support
infection by wild-type HIV [61]. Finally, we have recently
employed mouse microglial cells productively infected with HIV
through the use of VSV-G pseudotyped virus to explore immune
control of HIV in the brains of immunocompetent mice [49]. The
present work demonstrates further use of rodent cells as a suitable
model system for study of aspects of HIV neuropathogenesis that
require infection with intact HIV.
Astrocytes are well known to directly influence neuronal survival
and modulate the microenvironment of the nervous system by
affecting glutamate uptake and release, free radical scavenging,
water transport, and production of cytokines, chemokines and
nitric oxide [25,62–66]. Our results showing that astrocytes
attenuate neurotoxicity caused by HIV-1/VSV infected microglia
secretions support their noted regulatory function to contain
disease progression. This was previously confirmed by astrocyte-
mediated neuroprotection during the early stages of CNS injury or
microbial infection (reviewed in [67]). In support of this idea, we
not demonstrate that exposure of astrocytes to HIV-infected
microglia significantly reduces neuronal death. The astrocyte-
induced neuroprotective effect was shown to be associated with
alterations of the apoptosis signaling pathway by multiple
mechanisms. First, astrocytes attenuated microglial death protein
expression while affecting an up-regulation of cell growth and
signal transduction proteins. This included the noted expression of
glutathione S-transferase mu1 (GSTM1), enolase-a, preoxiredoxin
1, galectin-3 and PP2A. Surprisingly, most of these proteins were
linked to reactive oxygen species production, such as NO by iNOS
and hydrogen peroxide (H2O2). iNOS was previously shown to
parallel the severity of HIV-associated neurocognitive disorders
(HAND) [68,69], and the addition of NO to HIV-infected cells
enhanced viral replication [70,71]. With respect to HIV-1
infection, Tat exposure of microglia leads to expression of iNOS
as well as NO production [72]. Second, proteins such as
preoxiredoxin 1 belongs to a family of enzymes that reduces
hydroperoxides and play a major role in the clearance of low
concentrations of H2O2 [73] and reduction of electrophilic
neurocytotoxicity. GSTM1 has high detoxifying activity for 4-
hydroxy-2-nonenal, the major hydroxylalkenal that is formed
during peroxidation of polyunsaturated fatty acid and is highly
cytotoxic to neuronal cells [74]. We demonstrated that astrocytes
significantly down-regulate GSTM1 in HIV-infected microglia
and attenuate HIV neurotoxicity by affecting NFkB signal
pathways which reduce iNOS activity and NO radicals [75,76].
Third, microglial NFkB pathway is attenuated by regulation of
MARCKS, enolase-a, calmodulin, and protein kinase C and
casein kinase substrate in neurons 2 (PACSIN2). MARCKS is a
major protein kinase C (PKC) substrate in a variety of cells
including brain MP [77]. Importantly, MARCKS interacts with
the plasma membranes of macrophages [78,79], neurons [80] and
fibroblasts [81]. The unphosphorylated form of MARCKS binds
to actin filaments, leading to cross linking and sequestration of
membrane phospholipids, whereas phosphorylation by PKC
abrogates membrane binding of MARCKS. MARCKS positively
affects brain development and neuronal survival, cellular migra-
tion and adhesion, as well as endo-, exo- and phago-cytosis, and
neurosecretion [78,81,82]. Our current study reveled that
MARCKS was reduced in microglia infected with HIV-1.
Enolase-a is a glycolytic enzyme described as a heat-shock protein
in yeast and shown to be an early target of oxidative damage by
carbonylation in different cell systems, ranging from yeast to
humans [83,84]. Interestingly, enolase-a significantly increases
intracellular Ca
2+, which leads to Bax translocation to the
mitochondria and release of cytochrome c into the cytoplasm
which correlates with the initiation of apoptosis and down-
with astrocytes (MCG+AST). Densitometric analysis of HIV-1 p24 levels were normalized to GAPDH levels and mean6SEM were determined for n=3
determinations. Differences between means were determined by one way ANOVA and Tukey’s post-hoc test for multiple comparisons where
*p,0.01. HIV-1 p24 expression was reduced from infected microglia after co-culture with astrocytes (MCG+AST) compared to that of MCG.
doi:10.1371/journal.pone.0002507.g005
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PLoS ONE | www.plosone.org 11 June 2008 | Volume 3 | Issue 6 | e2507Figure 6. BMM mobility after exposure to micoglia/astrocvte conditioned media. Migration of CMFDA-labeled BMM was assessed for 3 h
using confocal microscopy live imaging in m-slide chemotaxis assays comparing fresh media with conditioned media (CM) from microglia alone
(MCG), astrocytes alone (AST) or microglia-astrocyte co-cultures (MCG+AST). Inhibitors wiskostatin (WISK, 20 mM) and latrunculin A (LatA, 0.2 mg/ml)
were utilized to inhibit BMM migration. (A) Representative migrating BMM cultured in fresh medium (Medium) or CM fro microglia-astrocyte co-
cultures (MCG+AST) were tracked (X’s in different color tracings) and evaluated at 60 min, 120 min, and 180 min. Scale bar, 10 mm; original
magnification,610. (B) Plots of each individual cell migration were generated from tracking data acquired for 3 h cultures in medium (Fresh Medium),
CM from microglia (MCG), astrocytes (AST), or astrocyte-microglia co-cultures (CM), and in the presence of WISK and LatA inhibitors. Data were
acquired by laser confocal microscopy and ImageJ software (NIH) interfaced with the ManulTrack plugin. (C) Migration velocities for each individual
cell track were determined with the Chemotaxis and Tool software tool (ibidi). Significant differences in the mean6SEM migration velocities for n=50
determinations/group were assessed by two-tail Student’s t test where *p,0.05 was considered significant.
doi:10.1371/journal.pone.0002507.g006
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work that enolase-a was also reduced in HIV-infected microglia as
well [86]. Heat shock proteins (HSPs), especially HSP-70, known
as stress proteins, are induced upon cellular injury including
hypoxia ischemia, heat trauma, neurodegenerative disorder, viral
and bacterial infection, inflammation and oxidant injury [87] and
have diverse functions including regulation of the redox state,
modulation of protein turnover, and protection of CNS [88,89].
HSPs can also protect cells from the consequences of protein
misfolding and induce anti-apoptotic proteins, however, acute
HIV infection results in increased HSP-70 mRNA and protein
levels [90] and redistribution of HSP-70 on cell surface of the
infected cells [91]. HSP-70 incorporates other HSPs, such as HSP-
60, into the membrane of HIV-1 virions through Gag interactions
[92], which can augment immune responses. A recent study
demonstrated that HSP-70 also can protect astrocytes from cell
death induced by HIV proteins [34]. Furthermore, astrocytes
susceptible to neurotoxic processes and increased HSP-70 protein
that may point to a possible pivotal role of HSP-70 in the signaling
pathways of stress tolerance [93]. These discoveries are compatible
with our current study. In this study, we also showed microglial
biliverdin reductase, which converts biliverdin into antioxidant
bilirubin [94] was up-regulated after infected microglia were co-
cultured with astrocytes. Taken together, these results suggest
astrocytes attempt to regulate microglial activation as well as
productive HIV-1 infection via regulation of reactive oxygen
species-induced cell death pathways. A possible mechanism for this
regulation is the production of immunosuppressive factors, such as
indoleamine 2,3-dioxygenase, as well as other redox enzymes, such
as biliverdin reductase [95–98].
Mechanisms controlling over-activation represent a most
important means to avoid inflammation-related CNS injury,
which is a common factor associated with many severe
neurodegenerative diseases, such as HAND, Parkinson’s disease,
and multiple sclerosis (MS) [99–101]. Thus, astrocytic regulation
of microglial activation may be one of the reasons why HIV-1 p24
production was dramatically reduced when infected microglia
were co-cultured with astrocytes. Astrocytes regulate gene
expression, such as enhancing cell growth and signal transduction,
to overcome HIV-infected microglia active. PP2A is a phospho-
protein reported to affect HIV-1 transcription and viral replica-
tion, and inhibition of PP2A enzymatic activity compromises Tat-
induced HIV-1 transcription and viral production [102]. In
addition, increase of intracellular PP2A activity enhances
activation of HIV-1 promoter by phorbol myristate acetate
(PMA), whereas inhibition of PP2A prevents its activation [103].
In this study, we observed both in DIGE and Western blot assays
that microglia expressed significant less PP2A when co-cultured
with astrocytes compared to its expression in the absence of
astrocytes, regardless of microglial infection status. This implies
that astrocyte-mediated restriction on HIV-1 replication in
microglia is partly due to deregulation of microglial intracellular
PP2A.
Most significant in this study was the capacity of astrocytes to
alter the cytoskeletal protein network in viral infected-microglia.
The current work extends previous observations made in our
laboratories that actin and profilin rearrangement in human
macrophages, along with exosomal secretion, affect viral replica-
tion and cytopathicity [104]. HIV-1 infection of microglia
enhances F-actin and microtubule polarization which are both
essential for cell mobility. These responses can be modulated by
astrocytes via eliciting changes in the cytoskeleton protein network
associated with F-actin protein transformation. In contrast,
astrocytes affect HIV-infected microglial cytoskeleton proteins
that could lead to assembly of filaments and formation of plasma
membrane projections. For example, down-regulation of APC,
MAPRE1 and TPM3 were observed which are reported to
increase the microtubule polymerization [105,106]. Infected
microglia when co-cultured with astrocytes, up-regulated VIL2,
WASF2, and PACSIN2, all having been shown to positively affect
plasma membrane projections [107–110]. Recently, reports
suggest that MARCKS protein mediates regulation of the actin
cytoskeleton directly via binding and possibly cross-linking PIP2
dependent proteins [77]. Indeed, BMM migration was enhanced
by astrocytes. This was linked to actin polymerization, but may
also be linked to proteins that cap growing filaments, sever existing
filaments from older proteins, and control the availability of
activated actin monomers [111]. The latter is most important for
cells to form necessary polarities required for locomotion; the lack
of these proteins can lead to elongation of actin filaments and a
resting status instead of polarization and migration. This was
shown by comparison studies of proteomic and immunochemical
assays. The former studies showed that microglia in co-culture
with astrocytes exhibited a network merely increasing the
polymerization of actins without differential expression of severing
proteins supporting significant increases seen in elongated
microglial morphologies. This loss of the typical ramified
morphology for resting microglia after co-culture with astrocytes
and inhibition of PP2A activity was reported by others [112].
These findings support our results demonstrating a dramatic
down-regulation of microglial PP2A associated with profound
changes in cell morphology.
In conclusion, together with changes in cytoskeletal and cell
death pathways, modulation of glutamate transport and anti-
oxidant proteins were previously found in virus-infected astrocytes
or in microglia exposed to astrocyte secretions [113–115]. For
example, the astrocyte elevated gene (AEG)-1 is inducible in
infected astrocytes by HIV-1 and TNF-a. AEG-1 down-regulates
the expression of the glutamate transporter EAAT and as such, is
directly linked to glutamate-induced excitotoxic damage to
neurons during progressive HIV infection [116,117]. Moreover,
astrocytes also regulate oxidative damage, a critical component of
neuroinflammatory activities, seen throughout the breadth of
neurodegenerative diseases [118–120]. Functions of oxidative
damage for which astrocyte-mediated regulation is attributable
include abnormal protein clearance, depletion of the cellular
redox-balance, and interference with the cell cycle. These, taken
together ultimate affect neuronal survival. Therefore, identifica-
tion of specific proteins protected from oxidation is an important
means to best understand the types of communication pathways
developed in the current report. Previous works demonstrated that
b-actin, calreticulin precursor protein, and synovial sarcoma, X
breakpoint 5 (SSX5) isoform A were increased in oxidative
modifications by astrocytes exposed to Tat [35]. All together our
results provide new insights into astrocyte-mediated protection
against neurotoxicity seen during HIV-1 microglial infections.
Materials and Methods
Primary mouse microglia, astrocyte and neuron isolation
Embryonic day 18 old fetuses were harvested from terminally
anesthetized pregnant C57BL/6 mice. Animals were maintained
in sterile microisolator cages under pathogen-free conditions and
bred in accordance with ethical guidelines for care of laboratory
animals at the University of Nebraska Medical Center as set forth
by the National Institutes of Health. Cerebral cortices were
isolated and digested using 0.25% trypsin (Invitrogen, Carlsbad,
CA) in PBS for 15 mins at 37uC. Single-cell suspensions were
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microglia (MCG) and astrocytes (AST). For neurons cortical
isolates were seeded at a density of 1.2610
5 cells/well on poly-D-
lysine coated cover slips, placed in 24-well plates and maintained
for 10 days in neurobasal medium supplemented with 2% B27
(Invitrogen), penicillin/streptomycin and 0.5 mM L-glutamine
(Invitrogen). Primary neurons were determined to be .98% as
determined by staining for expression of microtubule-associated
protein-2 (MAP-2) and with DAPI for nuclei, while ,2% of the
cells expressed glial fibillary acidic protein (GFAP) (data not
shown). For microglia, cortical isolates were cultured for 14 days in
DMEM supplemented with 10% FBS, 2 mM L-glutamine, 1%
penicillin/streptomycin (all from Invitrogen), and 2 mg/ml mac-
rophage colony stimulating factor (MCSF) (a generous gift of
Wyeth Inc., Cambridge, MA, USA). For astrocytes, cortical
isolates were cultured for 14 days in DMEM supplemented with
F12, 10% FBS, 2 mM L-glutamine, and 1% penicillin/strepto-
mycin (all from Invitrogen).
Single culture and transwell co-culture
For single cell-type cultures in 6-well plates, microglia were
seeded at 2610
6 cells/well and astrocytes at 1610
6 cells/well. For
co-culture, uninfected or infected microglia were seeded in 6-well
culture plates at 2610
6 cells/well and cultured for 3 d before
adding transwell inserts containing uninfected astocytes at
1610
5 cells/insert. Importantly, conditioned media (CM) pre-
pared from either single cell-type or co-cultures were mixed and
utilized at a 1:1 ratio of microglial CM and astrocyte CM from the
above cultures.
Viruses and infection
Vesicular stomatitis virus (VSV) pseudotyped HIV-1 strain YU2
was used to circumvent receptor HIV-1 co-receptor requirements
and infect mouse cells. Cells were infected with HIV-1/VSV at a
final concentration of 1 pg HIV-1 p24 per cell for 24 h prior to
rinsing and were cultured for 7 days before use. Greater than 98%
of microglia were infected as determined by immunohistochemical
staining for HIV-1 p24 (data not shown).
TUNEL assay
Terminal deoxynucleotidyl transferase-mediated biotinylated
UTP nick end labeling (TUNEL) was performed using the in situ
cell death detection kit, AP (Roche Applied Science, Indianapolis,
IN) according to the manufacturer’s instructions. Briefly, neurons
were fixed with 4% paraformaldehyde in PBS (pH 7.4) and
permeabilized with 0.1% TritonX-100 in 0.1% sodium citrate.
Cells were subsequently labeled with TUNEL working solution.
Apoptotic cells were identified as green fluorescent TUNEL
positive cells by fluorescence microscopy, and were normalized to
total number of cells as determined by DAPI nuclear staining.
Protein sample preparation
Cells were washed in PBS, harvested and lysed in 200 ml cell
lysis buffer containing 7 M urea, 2 M thiourea, 4% 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate
(CHAPS) (pH 8.5) and 16 protease inhibitor cocktail (Biovision,
Mountain View, CA). Cell lysates were sonicated at 25 W for 3
pulses at 3 sec per pulse (W-225 Sonicator, Heat Systems-
Ultrasonics, Inc., Farmingdale, NY). To remove impurities and
sample concentration, cell lysates were treated with a 2D Clean
Up Kit (GE Healthcare, Piscataway, NJ) according to the
manufacturer’s instructions. Protein concentration was determined
with the 2D Quant Kit (GE Healthcare).
Difference gel electrophoresis (DiGE) and image analysis
Fifty micrograms of protein sample from uninfected or HIV-1/
VSV-infected microglia were respectively labeled with 400 pmol
of Cy3 or Cy5 (CyDye Minimum Labeling kit, GE Healthcare).
Twenty-five micrograms of unlabeled protein from each sample
were mixed and labeled Cy2 (GE Healthcare) to serve as internal
standards. The resulting Cy2-, Cy3-, and Cy5-labeled cells were
pooled and mixed with rehydration buffer (7 M urea, 2 M
thiourea, 2% CHAPS, 50 mM DTT, 1% Pharmalyte (pH 3–
10NL). Labeled protein samples were loaded onto gel strips with
an immobilized pH gradient (24 cm; pH 3–10 NL) and the first-
dimension separation was achieved by isoelectric focusing
(IPGphor II, GE Healthcare) for 1 h at 500 V, 1 h at 1000 V,
and 3 h at 8000 V. The focused strips were treated with
equilibration solution [6 M urea, 30% glycerol, 2% sodium
dodecyl sulfate (SDS), 50 mM Tris (pH 8.8)] containing 100 mM
DTT for 10 min. Thereafter, strips were alkylated with 100 mM
iodacetamide (Sigma-Aldrich, St Louis, MO) in equilibration
solution for 10 min. Immediately after, gel strips were placed on
top of a 10–20% polyacrylamide gradient reducing gel and 2
nd
dimension separation was achieved by electrophoresis at constant
5 mA for the initial 30 min and 12 mA for 14 h. For visualization
of protein spots, gels were read with a 2D Master Imager (GE
Healthcare) at excitation wavelengths of 488 nm, 520 nm, and
620 nm and emission wavelengths of 520 nm, 590 nm, and
680 nm to detect Cy2-, Cy3-, and Cy5-labeled proteins,
respectively. The relative protein amount for each spot was
determined by digital quantification using DeCyder-DIA software
(GE Healthcare). Protein levels exhibiting greater than 1.5-fold
changes above or below relative amounts after normalization were
considered candidates for further analyses as an arbitrary cut off.
Spot picking and in-gel tryptic digestion
Protein spots within 2 mm
2 fragments were robotically picked
from the gel using the Ettan
TM Spot Picker (GE Healthcare) and
destained for 1 h at room temperature using 100 ml of 50%
acetonitrile (ACN)/50 mM NH4HCO3. Gel fragments were dried
and incubated with 0.25% trypsin/10 mM NH4HCO3 (Promega)
overnight at 37uC. Peptides were extracted by washing gel pieces
twice with 0.1% trifluroacetic acid (TFA) and 60% ACN.
Mass spectrometry
All samples were purified using ZipTipH (Millipore) prior to
mass spectrometric analysis. Peptide samples were resuspended in
0.1% formic acid/HPLC-grade water and analyzed by LC/MS/
MS (LCQ DECA XPPlus, ThermoElectron, Inc. Waltham, MA)
and MALDI-Tof-Tof mass spectrometry (ABI 4800, Applied
Biosystems, Foster City, CA). Proteins were identified from the
NCBI database interfaced with BioWorks 3.1SR software
(ThermoElectron). Protein identifications scoring greater than
3000 by the Unified Score scale and greater than 50% on ion
score were considered for further analyses. For MALDI-Tof-Tof,
peptide samples in a-cyano-4-hydroxycinnamic acid (CHCA;
Sigma-Aldrich) matrix were spotted on to Opti-TOFH 384 well
MALDI plate inserts (Applied Biosystems). The mass profile
analyzed by the MALDI-TOF-TOF mass spectrometer was
searched in Mascot database assisted by GPS Explorer software
(Applied Biosystems) and only significant protein identifications
(p,0.05) were considered for further analyses.
Ingenuity pathway analysis
A data set containing protein identifiers and corresponding
expression values was uploaded into in the application Ingenuity
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its corresponding gene in the database and networks of these focus
genes were algorithmically generated based on their connectivity.
The Functional Analysis identified the biological functions and/or
diseases that were algorithmically significant to the data set. The
graphical representation of the molecular relationships between
genes/gene products are represented as nodes, and the biological
relationship between two nodes is represented as an edge (line). All
edges are supported by at least 1 reference from the literature,
from a textbook, or from canonical information stored in the
Ingenuity Pathways Knowledge (IngenuityH Systems, www.
ingenuity.com).
Immunohistochemistry
Cells adhered to cover slips were fixed and permeabilized with
acetone and methanol (ratio 1:1, at 220uC) for 10 min, and
nonspecific activity was blocked by incubation of fixed cells in 6%
BSA/PBS. Blocked samples were reacted with 250 ml of diluted
corresponding primary antibody which included mouse anti-
neuron-specific nuclear protein (NeuN) (1/100; Chemicon,
Temecula, CA), rabbit anti- microtubule associate protein-2
(MAP-2) (1/1000; Chemicon), rabbit anti-tubulin-a (1:1000;
Novus, Littleton, CO), rabbit anti-ionized calcium binding
adaptor molecule 1 (Iba-1) (1:500, Wako, Richmond, VA), and
mouse-anti-vimentin (1:1000; Dako, Carpenteria, CA). F-actin
was detected with rhodamine-conjugated phalloidin (Invitrogen).
Primary antibody reacted cells were incubated with 250 ml of the
appropriate diluted goat anti-mouse or goat anti-rabbit Abs
secondary antibodies (1:250; Invitrogen) conjugated to Alexa-488
or Alexa-568. Cells were mounted using anti-fade Pro-Long Gold
mounting reagent (Invitrogen) and examined with a Zeiss LSM
510 META NLO microscope (Zeiss MicroImaging, Inc., Thorn-
wood, NY).
Western Blotting
For Western blots, 10 mg of protein from each total cell lysate
was electrophorectically separated on SDS-PAGE and electro-
transfered to polyvinylidene membranes (Roche). Membranes
were incubated overnight at 4uC with specific primary antibodies
including, mouse anti-PP2A (1:500; Cell signaling, Danvers, MA),
mouse anti-vimentin (1:500; Dako), rabbit anti-tubulin-a (1:1000;
Novus), rabbit anti-biliverdin reductase (1:5000; Abcam, Cam-
bridge, MA), rabbit anti-enolase-a (1:1000; Santa Cruz, Santa
Cruz, CA), mouse anti-calmodulin (1:1000; Abcam), mouse anti-
HIV-1 p24 (1:500; Dako) or rabbit anti-caspase-3 (1:1000; Cell
signaling). Detection of reacted primary antibodies was achieved
with horseradish peroxidase (HRP)-conjugated goat anti-mouse
(1:10,000) or goat anti–rabbit (1:10,000) IgG antibodies (Jackson
Immunoresearch, West Grove, PA.) HRP activity was visualized
by an enhanced chemiluminescence detection procedure (Pierce,
Rockford, IL).
Chemotaxis assay
BMM were isolated from femur bone marrow of C57BL/6
mice, and were dissociated into single cell suspensions. Bone
marrow cells were seeded to Teflon-coated flasks at 2610
6 cells/
ml in DMEM supplemented with 10% FBS, 2 mM L-glutamine,
1% penicillin/streptomycin (complete DMEM), and 2 mg/ml of
MCSF (a gift from Wyeth) and cultured for 7 days. For chemotaxis
assay, BMM were labeled with 10 mM CMFDA (Invitrogen) in
DMEM at 37uC for 40 min, washed, and adjusted to
2.5610
6 cells/ml in complete DMEM. CMFDA-labeled cell
suspensions were introduced into the m-slides (ibidi, LLC, Verona,
WI) in 10 ml per chamber and cultured for 35 min in the humid
cell incubator at 37uC to allow cell attachment. Fresh or
conditioned media (CM) were loaded to the two reservoirs on
both sides of each chamber and cells were imaged for 3 h using a
Nikon Swept-Field laser confocal microscope (Nikon Instruments,
New York, NY). Images were analyzed using different plugins
interfaced with ImageJ 1.386 software (Rasband, W.S., ImageJ,
U. S. National Institutes of Health, Bethesda, Maryland, USA,
http://rsb.info.nih.gov/ij/, 1997–2007). Migration co-ordination
data for each observed cell was acquired with the ManulTrack
plugin (Fabrice Cordelie `res, Institut Curie, Orsay, France).
Chemotaxis plots and migration velocities of each cell were
determined with the Chemotaxis and Migration Tool (ibidi).
Statististics
All resulting data were analyzed for statistical significance either
by two-tail Student’s t-test or one-way ANOVA with Tukey’s post-
hoc multiple comparisons using GraphPad Prism version 4.0
(GraphPad Software, Inc., San Diego, CA). P,0.05 was deemed
significant.
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